The BE (2)-M17 neuroblastoma cell line synthesizes and secretes corticotropin-releasing factor

John W. Kasckow, David G. Parkes, Michael J. Owens, Mark D. Stipetic, Jin Hee Han, Charles B. Nemeroff, Wylie W. Vale

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The BE (2)-M17 human neuroblastoma has previously been show to express corticotropin-releasing factor (CRF) mRNA following retinoic acid treatment. It is demonstrated in this report that both cell extracts and cell incubation medium of retinoic acid-treated BE (2)-M17 cells were shown to contain CRF-like immunoreactivity (CRF-LI) by RIA. CRF-LI secretion and content were also dose-dependently increased by forskolin. In addition, cell extracts were applied to a C18 Vydac column and peak CRF-LI from the collected fractions was shown to coincide in time of elution with peak immunoreactivity seen with oxidized synthetic CRF standard. Thus, in containing the CRF peptide, the BE (2)-M17 cells are useful models for further study of CRF cellular and genetic regulation.

Original languageEnglish (US)
Pages (from-to)159-162
Number of pages4
JournalBrain research
Issue number1
StatePublished - Aug 15 1994
Externally publishedYes


  • BE (2)-M17
  • Forskolin
  • HPLC
  • Neuroblastoma
  • orticotropin-releasing factor
  • RIA

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'The BE (2)-M17 neuroblastoma cell line synthesizes and secretes corticotropin-releasing factor'. Together they form a unique fingerprint.

Cite this